Comparative Study
doi: 10.1007/BF01297125.
The effect of 15(R)-15-methyl prostaglandin E2 on meal-stimulated gastric acid secretion, serum gastrin, and pancreatic polypeptide in duodenal ulcer patients
- PMID: 456224
- DOI: 10.1007/BF01297125
Item in Clipboard
Comparative Study
The effect of 15(R)-15-methyl prostaglandin E2 on meal-stimulated gastric acid secretion, serum gastrin, and pancreatic polypeptide in duodenal ulcer patients
Dig Dis Sci.
1979 May.
Abstract
The effects of 100-microgram of 15(R)-15-methyl prostaglandin E2 on meal-stimulated acid secretion, serum gastrin, and pancreatic polypeptide concentrations were measured in patients with duodenal ulcer. The drug given in encapsulated or unencapsulated form significantly reduced gastric acid secretion by 59% or 70%, respectively. Rises in serum gastrin and pancreatic polypeptide concentrations after the meal were significantly blunted by 15(R)-15-methyl prostaglandin E2. This dose of prostaglandin led to no side effects and merits clinical evaluation in the treatment of peptic ulcer disease.
Similar articles
-
Effect of orally administered 15(R)-15-methyl prostaglandin E2 and/or an anticholinergic drug on meal-induced gastric acid secretion and serum gastrin level in patients with duodenal ulcers.Scand J Gastroenterol. 1979;14(7):813-9. doi: 10.3109/00365527909181409. Scand J Gastroenterol. 1979. PMID: 395627 Clinical Trial.
-
Prostaglandins and vagal stimulation of gastric secretion in duodenal ulcer patients.Scand J Gastroenterol. 1983 Jan;18(1):43-7. doi: 10.3109/00365528309181557. Scand J Gastroenterol. 1983. PMID: 6426038
-
Enprostil, a synthetic prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcer.Am J Med. 1986 Aug 18;81(2A):44-9. doi: 10.1016/s0002-9343(86)80010-9. Am J Med. 1986. PMID: 3092654 Clinical Trial.
-
Effect of oral and intravenous 16,16-dimethyl prostaglandin E2 in duodenal ulcer and Zollinger-Ellison syndrome patients.Gastroenterology. 1981 Jan;80(1):55-9. Gastroenterology. 1981. PMID: 7450412 Clinical Trial.
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
Cited by
-
Diflunisal protects human gastric mucosa against damage by indomethacin.Dig Dis Sci. 1983 Dec;28(12):1070-7. doi: 10.1007/BF01295804. Dig Dis Sci. 1983. PMID: 6581036 Clinical Trial.
-
Effect of rioprostil, a methylprostaglandin E1 analog, on basal and stimulated plasma pancreatic hormone levels in man.Dig Dis Sci. 1990 Jan;35(1):20-6. doi: 10.1007/BF01537217. Dig Dis Sci. 1990. PMID: 2104796
-
Reduction of aspirin-induced fecal blood loss with low-dose misoprostol tablets in man.Dig Dis Sci. 1985 Jul;30(7):605-11. doi: 10.1007/BF01308407. Dig Dis Sci. 1985. PMID: 3924533 Clinical Trial.
-
Arbaprostil (15(R)-15-methyl PGE2): lack of effect on theophylline metabolism.Br J Clin Pharmacol. 1986 Feb;21(2):239-41. doi: 10.1111/j.1365-2125.1986.tb05183.x. Br J Clin Pharmacol. 1986. PMID: 3954940 Free PMC article. Clinical Trial. No abstract available.
-
Absorption, tissue distribution, and excretion of 3H-labeled arbaprostil in the male rat.Eur J Drug Metab Pharmacokinet. 1985 Apr-Jun;10(2):171-7. doi: 10.1007/BF03189712. Eur J Drug Metab Pharmacokinet. 1985. PMID: 4043145